Ads
related to: clinical aspects of neoplasia blood disorder- Request Representative
Fill Out A Brief Form To Request
Assistance From A Representative.
- Physician Resources
Find Programs & Support Resources
To Share With Your IMFINZI Patients
- Order Brochures Here
Download An Instructional Brochure
On Ordering IMFINZI For Patients.
- Safety Information
Learn About Safety & Efficacy
Information For IMFINZI.
- Request Representative
Search results
Results From The WOW.Com Content Network
The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant. The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).
Aggressive NK-cell leukemia is a disease with an aggressive, systemic proliferation of natural killer cells (NK cells) and a rapidly declining clinical course. [ 1 ] [ 2 ] [ 3 ] It is also called aggressive NK-cell lymphoma .
Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Hematologic diseases are disorders which primarily affect the blood and blood-forming organs. Hematologic diseases include rare genetic disorders, anemia , HIV , sickle cell disease and complications from chemotherapy or transfusions.
CMML shows characteristics of a myelodysplastic syndrome (MDS); a disorder that produces abnormal looking blood cells, and a myeloproliferative neoplasm (MPN); a disorder characterised by the overproduction of blood cells. For this reason, CMML was reclassified as a MDS/MPN overlap disorder in 2002. [2]
One or more somatic mutations otherwise found in patients with myeloid neoplasms detected in bone marrow or peripheral blood cells with an allele burden of ≥ 2%; Persistent cytopenia (≥ 4 months) in one or more peripheral blood cell lineages; Diagnostic criteria of myeloid neoplasm not fulfilled